Towards PET imaging of the dynamic phenotypes of microglia
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
There is increasing evidence showing the heterogeneity of microglia activation in neuroinflammatory and neurodegenerative diseases. It has been hypothesized that pro-inflammatory microglia are detrimental and contribute to disease progression, while anti-inflammatory microglia play a role in damage repair and remission. The development of therapeutics targeting the deleterious glial activity and modulating it into a regenerative phenotype relies heavily upon a clearer understanding of the microglia dynamics during disease progression and the ability to monitor therapeutic outcome in vivo. To that end, molecular imaging techniques are required to assess microglia dynamics and study their role in disease progression as well as to evaluate the outcome of therapeutic interventions. Positron emission tomography (PET) is such a molecular imaging technique, and provides unique capabilities for non-invasive quantification of neuroinflammation and has the potential to discriminate between microglia phenotypes and define their role in the disease process. However, several obstacles limit the possibility for selective in vivo imaging of microglia phenotypes mainly related to the poor characterization of specific targets that distinguish the two ends of the microglia activation spectrum and lack of suitable tracers. PET tracers targeting translocator protein 18 kDa (TSPO) have been extensively explored, but despite the success in evaluating neuroinflammation they failed to discriminate between microglia activation statuses. In this review, we highlight the current knowledge on the microglia phenotypes in the major neuroinflammatory and neurodegenerative diseases. We also discuss the current and emerging PET imaging targets, the tracers and their potential in discriminating between the pro- and anti-inflammatory microglia activation states.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.026 · Cited by 4,089
Microglia Function in the Central Nervous System During Health and Neurodegeneration
Colonna, M., & Butovsky, O. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052358 · Cited by 2,894
Microglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935 · cited 3×
“The stimulation of TREM2 initiates signal transduction pathways that promote microglial chemotaxis, phagocytosis, survival and proliferation, suggesting an anti- inflammatory and protective role of DAM in AD [34,38].”
BackgroundNeuroinflammation and M2 Microglia: The Good, the Bad, and the Inflamed
Cherry, J. D., Olschowka, J. A., & O’Banion, M. K. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-98 · Cited by 1,748
A polarizing question: do M1 and M2 microglia exist?
Ransohoff, R. M. (2016) · Nature Neuroscience · doi:10.1038/nn.4338 · Cited by 1,573
Yeh, F. L., Wang, Y., Tom, I., Gonzalez, L. C., & Sheng, M. (2016) · Neuron · doi:10.1016/j.neuron.2016.06.015 · Cited by 943 · cited 1×
“TREM2- deficient microglia showed reduced uptake of Aβlipoprotein complexes in vitro and minimal evidence of Aβ internalization in vivo [36,37].”
BackgroundMinocycline: Far beyond an Antibiotic
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12139 · Cited by 935
Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain
Alliot, F., Godin, I., & Pessac, B. (1999) · Developmental Brain Research · doi:10.1016/s0165-3806(99)00113-3 · Cited by 884 · cited 1×
“They originate from the yolk sac where progenitors, during development, migrate and populate the brain [1,2].”
BackgroundKim, C., Ho, D.-H., Suk, J.-E., You, S., Michael, S., Kang, J., Joong Lee, S., Masliah, E., Hwang, D., Lee, H.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms2534 · Cited by 856 · cited 8×
“Pro- inflammatory microglia are generally described as producers of inflammatory mediators, including tumor necrosis factor (TNF)- α, interleukin (IL)- 1β, IL- 6, macrophage inflammatory protein (MIP)- 1 α, nitric oxide synthase (NOS) and reactive oxygen species (ROS), via which they exert their detrimental effects [7…”
BackgroundInfluentialYuan, P., Condello, C., Keene, C. D., Wang, Y., Bird, T. D., Paul, S. M., Luo, W., Colonna, M., Baddeley, D., & Grutzendler, J. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.003 · Cited by 817
TREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function
Zhao, Y., Wu, X., Li, X., Jiang, L.-L., Gui, X., Liu, Y., Sun, Y., Zhu, B., Piña-Crespo, J. C., Zhang, M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.031 · Cited by 763
Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution
Mathys, H., Adaikkan, C., Gao, F., Young, J. Z., Manet, E., Hemberg, M., De Jager, P. L., Ransohoff, R. M., Regev, A., & Tsai, L.-H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.039 · Cited by 740
Coupled Proliferation and Apoptosis Maintain the Rapid Turnover of Microglia in the Adult Brain
Askew, K., Li, K., Olmos-Alonso, A., Garcia-Moreno, F., Liang, Y., Richardson, P., Tipton, T., Chapman, M. A., Riecken, K., Beccari, S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.041 · Cited by 726 · cited 1×
“Following this migration, the microglia population is maintained during the lifespan by self- renewal through apoptosis and proliferative processes [3].”
BackgroundInfluentialLoss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis
Zrzavy, T., Hametner, S., Wimmer, I., Butovsky, O., Weiner, H. L., & Lassmann, H. (2017) · Brain · doi:10.1093/brain/awx113 · Cited by 684 · cited 9×
“T A B L E 1 Activated microglia phenotypes and the expressed cytokines and markers in neuroinflammatory and neurodegenerative diseases Disease Microglia phenotype Expression of markers and cytokines Reference Multiple sclerosis Initial and early white matter active lesions Pro- inflammatory CD68, MHC- I, MHC- II, CD86…”
BackgroundInfluentialMicroglial exosomes facilitate α-synuclein transmission in Parkinson’s disease
Guo, M., Wang, J., Zhao, Y., Feng, Y., Han, S., Dong, Q., Cui, M., & Tieu, K. (2020) · Brain · doi:10.1093/brain/awaa090 · Cited by 522
Inflammatory Regulators in Parkinson's Disease: iNOS, Lipocortin-1, and Cyclooxygenases-1 and -2
Knott, C., Stern, G., & Wilkin, G. P. (2000) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0914 · Cited by 503 · cited 1×
“In post- mortem PD tissues, activated microglia express high levels of inflammatory cytokines such as IL- 1β, IL- 6 and TNF- α, as well as iNOS and cyclooxygenase- 2 (COX- 2), suggesting a proinflammatory activated phenotype [43,44].”
BackgroundNew insights into the role of TREM2 in Alzheimer’s disease
Gratuze, M., Leyns, C. E. G., & Holtzman, D. M. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0298-9 · Cited by 489
Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status
Vogel, D. Y., Vereyken, E. J., Glim, J. E., Heijnen, P. D., Moeton, M., van der Valk, P., Amor, S., Teunissen, C. E., van Horssen, J., & Dijkstra, C. D. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-35 · Cited by 479 · cited 1×
“In later stages of active lesions and inactive microglia- containing cores of active lesions, microglia adopted an intermediate phenotype and co- expressed anti- inflammatory markers (CD206 and CD163) together with pro- inflammatory markers [14,16,17].”
BackgroundCosenza‐Nashat, M., Zhao, M. ‐., Suh, H. ‐., Morgan, J., Natividad, R., Morgello, S., & Lee, S. C. (2009) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.01006.x · Cited by 459 · cited 2×
“In post- mortem human AD brain samples, TSPO expression was demonstrated in microglia, macrophages and astrocytes but also in cells surrounding Aβ plaques [62] and only marginally significant differences in TSPO protein expression were found in temporal and frontal cortex between AD patients and healthy controls [63].”
BackgroundDistinct amyloid-β and tau-associated microglia profiles in Alzheimer’s disease
Gerrits, E., Brouwer, N., Kooistra, S. M., Woodbury, M. E., Vermeiren, Y., Lambourne, M., Mulder, J., Kummer, M., Möller, T., Biber, K., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02263-w · Cited by 441
Dark microglia: A new phenotype predominantly associated with pathological states
Bisht, K., Sharma, K. P., Lecours, C., Gabriela Sánchez, M., El Hajj, H., Milior, G., Olmos‐Alonso, A., Gómez‐Nicola, D., Luheshi, G., Vallières, L., et al. (2016) · Glia · doi:10.1002/glia.22966 · Cited by 421
Jimenez, S., Baglietto-Vargas, D., Caballero, C., Moreno-Gonzalez, I., Torres, M., Sanchez-Varo, R., Ruano, D., Vizuete, M., Gutierrez, A., & Vitorica, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3024-08.2008 · Cited by 383 · cited 4×
“advanced stage of disease in this model, which is induced in part by the age- dependent accumulation of soluble Aβ oligomers [30].”
BackgroundInfluentialGold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361
Mildner, A., Huang, H., Radke, J., Stenzel, W., & Priller, J. (2017) · Glia · doi:10.1002/glia.23097 · Cited by 301 · cited 2×
“Receptor expression in the CNS is mainly restricted to microglia and P2Y12R is absent in peripheral macrophages, making it an ideal microglial marker [91].”
BackgroundCortical lesions in multiple sclerosis
Calabrese, M., Filippi, M., & Gallo, P. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.93 · Cited by 269
Sobue, A., Komine, O., Hara, Y., Endo, F., Mizoguchi, H., Watanabe, S., Murayama, S., Saito, T., Saido, T. C., Sahara, N., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01099-x · Cited by 253 · cited 10×
“The stimulation of TREM2 initiates signal transduction pathways that promote microglial chemotaxis, phagocytosis, survival and proliferation, suggesting an anti- inflammatory and protective role of DAM in AD [34,38].”
BackgroundInfluentialFerrari, C. C., Pott Godoy, M. C., Tarelli, R., Chertoff, M., Depino, A. M., & Pitossi, F. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.06.013 · Cited by 235
The microglial ATP‐gated ion channel P2X7 as a CNS drug target
Bhattacharya, A., & Biber, K. (2016) · Glia · doi:10.1002/glia.23001 · Cited by 221 · cited 2×
“High ATP concentrations (mM), generally an effect of cell damage or injury, are required to trigger receptor activation [73,74].”
BackgroundBoissonneault, V., Filali, M., Lessard, M., Relton, J., Wong, G., & Rivest, S. (2008) · Brain · doi:10.1093/brain/awn331 · Cited by 221
Microglia and Neuroinflammation: What Place for P2RY12?
Gómez Morillas, A., Besson, V. C., & Lerouet, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041636 · Cited by 214 · cited 1×
“In MS, P2Y12R expression is absent in the active and chronic active lesions [14,91] and in AD a loss of P2Y12R expression is observed in microglia surrounding Aβ plaques and Tau tangles [95].”
BackgroundP2Y12 expression and function in alternatively activated human microglia
Moore, C. S., Ase, A. R., Kinsara, A., Rao, V. T. S., Michell-Robinson, M., Leong, S. Y., Butovsky, O., Ludwin, S. K., Séguéla, P., Bar-Or, A., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000080 · Cited by 212 · cited 2×
“In a model of parasitic brain infection known to induce a T helper type 2 (Th- 2) response that promotes anti- inflammatory microglia polarization, P2Y12R expression was highly increased on CD163positive microglia [92].”
BackgroundMethodHoward, R., Zubko, O., Bradley, R., Harper, E., Pank, L., O’Brien, J., Fox, C., Tabet, N., Livingston, G., Bentham, P., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3762 · Cited by 194
Cellular sources of TSPO expression in healthy and diseased brain
Nutma, E., Ceyzériat, K., Amor, S., Tsartsalis, S., Millet, P., Owen, D. R., Papadopoulos, V., & Tournier, B. B. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05166-2 · Cited by 192
Peferoen, L. A. N., Vogel, D. Y. S., Ummenthum, K., Breur, M., Heijnen, P. D. A. M., Gerritsen, W. H., Peferoen-Baert, R. M. B., van der Valk, P., Dijkstra, C. D., & Amor, S. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000149 · Cited by 178 · cited 1×
“In later stages of active lesions and inactive microglia- containing cores of active lesions, microglia adopted an intermediate phenotype and co- expressed anti- inflammatory markers (CD206 and CD163) together with pro- inflammatory markers [14,16,17].”
BackgroundHughes, C. D., Choi, M. L., Ryten, M., Hopkins, L., Drews, A., Botía, J. A., Iljina, M., Rodrigues, M., Gagliano, S. A., Gandhi, S., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1907-y · Cited by 177 · cited 8×
“Pro- inflammatory microglia are generally described as producers of inflammatory mediators, including tumor necrosis factor (TNF)- α, interleukin (IL)- 1β, IL- 6, macrophage inflammatory protein (MIP)- 1 α, nitric oxide synthase (NOS) and reactive oxygen species (ROS), via which they exert their detrimental effects [7…”
BackgroundInfluentialScalzo, P., Kümmer, A., Cardoso, F., & Teixeira, A. L. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2009.10.062 · Cited by 175
Activated microglia drive demyelination via CSF1R signaling
Marzan, D. E., Brügger‐Verdon, V., West, B. L., Liddelow, S., Samanta, J., & Salzer, J. L. (2021) · Glia · doi:10.1002/glia.23980 · Cited by 172
Martin, E., Boucher, C., Fontaine, B., & Delarasse, C. (2017) · Aging Cell · doi:10.1111/acel.12522 · Cited by 156
Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis
Sucksdorff, M., Matilainen, M., Tuisku, J., Polvinen, E., Vuorimaa, A., Rokka, J., Nylund, M., Rissanen, E., & Airas, L. (2020) · Brain · doi:10.1093/brain/awaa275 · Cited by 142 · cited 2×
“Interestingly, this is the first clinical study, to our knowledge, showing that higher TSPO binding predicts greater clinical disability, independent of relapsing status [69].”
BackgroundMethodA quantitative neuropathological assessment of translocator protein expression in multiple sclerosis
Nutma, E., Stephenson, J. A., Gorter, R. P., de Bruin, J., Boucherie, D. M., Donat, C. K., Breur, M., van der Valk, P., Matthews, P. M., Owen, D. R., et al. (2019) · Brain · doi:10.1093/brain/awz287 · Cited by 138 · cited 2×
“Moreover, TSPO expression was also shown not to be phenotype- specific in microglia in active and chronic active MS lesions [64].”
BackgroundWalker, D. G., Tang, T. M., Mendsaikhan, A., Tooyama, I., Serrano, G. E., Sue, L. I., Beach, T. G., & Lue, L.-F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020678 · Cited by 128
van Olst, L., Rodriguez-Mogeda, C., Picon, C., Kiljan, S., James, R. E., Kamermans, A., van der Pol, S. M. A., Knoop, L., Michailidou, I., Drost, E., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02293-4 · Cited by 87 · cited 9×
“Interestingly, only MS2 microglia were associated with neuronal loss in the cortical lesions [21].”
BackgroundInfluentialMartínez-Frailes, C., Di Lauro, C., Bianchi, C., de Diego-García, L., Sebastián-Serrano, Á., Boscá, L., & Díaz-Hernández, M. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00143 · Cited by 83
Böttcher, C., van der Poel, M., Fernández-Zapata, C., Schlickeiser, S., Leman, J. K. H., Hsiao, C.-C., Mizee, M. R., Adelia, Vincenten, M. C. J., Kunkel, D., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01010-8 · Cited by 58 · cited 4×
“Recent discoveries of specific markers and molecular signatures of microglia [transmembrane protein 119 (TMEM119) and purinergic 2Y receptor type 12 (P2Y12R)] indicated their predominance over monocytederived macrophages in MS lesions [14,15].”
BackgroundInfluential
Cited by
Emerging diagnostics and therapeutics for Alzheimer disease
Self, W. K., & Holtzman, D. M. (2023) · Nature Medicine · doi:10.1038/s41591-023-02505-2 · Cited by 381
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119
Neurogenesis and Neuroinflammation in Dialogue: Mapping Gaps, Modulating Microglia, Rewiring Aging
Tanaka, M. (2026) · Cells · doi:10.3390/cells15010078 · Cited by 11
“New PET tracers are being developed to distinguish pro-and anti-inflammatory microglial phenotypes or to directly visualize neurogenic processes, promising greater specificity than TSPO-based tools [218].”
Non-invasive in vivo imaging of brain and retinal microglia in neurodegenerative diseases
Etebar, F., Harkin, D. G., White, A. R., & Dando, S. J. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1355557 · Cited by 7
Integrative network analysis reveals novel moderators of Aβ-Tau interaction in Alzheimer's disease
Kitani, A., Matsui, Y., & Initiative, F. T. A. D. N. (2025) · Alzheimer's Research & Therapy · doi:10.1186/s13195-025-01705-x · Cited by 6
“Notably, P2X7R and P2Y12R have been highlighted as tracers for pro-inflammatory and anti-inflammatory phenotypes, respectively [74], and GPNMB also has the potential to serve as a tracer for microglial subtypes.”
Metadata
- Authors
- Beaino, W., Janssen, B., Vugts, D. J., de Vries, H. E., & Windhorst, A. D.
- Venue
- Clinical and Experimental Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-08-16
- Volume
- 206
- Issue
- 3
- Pages
- 282-300
- ISSN
- 0009-9104 (ISSN-L)
- 1365-2249
- OpenAlex
- W3184333798
- Cited by
- 61
- References
- 45
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.